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Abstract 
Rationale: Alpha particle emitting radiopharmaceuticals are generating considerable interest for the 
treatment of disseminated metastatic disease. Molecular imaging of the distribution of these agents is 
critical to safely and effectively maximize the clinical potential of this emerging drug class. The present 
studies aim to investigate the feasibility and limitations of quantitative SPECT for 223Ra, 225Ac and 227Th. 
Methods: Three state-of-the-art SPECT/CT systems were investigated: the GE Discovery NM/CT 670, 
the GE Optima NM/CT 640, and the Siemens Symbia T6. A series of phantoms, including the NEMA IEC 
Body phantom, were used to compare and calibrate each camera. Additionally, anthropomorphic physical 
tumor and vertebrae phantoms were developed and imaged to evaluate the quantitative imaging 
protocol. 
Results: This work describes and validates a methodology to calibrate each clinical system. The efficiency 
of each gamma camera was analyzed and compared. Using the calibration factors obtained with the 
NEMA phantom, we were able to quantify the activity in 3D-printed tissue phantoms with an error of 
2.1%, 3.5% and 11.8% for 223Ra, 225Ac, and 227Th, respectively. 
Conclusion: The present study validates that quantitative SPECT/CT imaging of 223Ra, 225Ac, and 227Th is 
achievable but that careful considerations for camera configuration are required. These results will aid in 
future implementation of SPECT-based patient studies and will help to identify the limiting factors for 
accurate image-based quantification with alpha particle emitting radionuclides. 
Key words: radiopharmaceutical therapies; quantitative SPECT/CT; Radium-223; Actinium-225; Thorium-227 
Introduction 
The application of radiation to treat primary and 
oligometastatic disease is a pillar of cancer therapy, 
demonstrating efficacy in a wide range of cancer 
types. However, in the metastatic setting, image- 
guided application of conventional external beam 
irradiation is generally limited to palliative use. This 
is because the inherent challenges in safely and 
effectively applying sufficient dose to multiple sites 
throughout the body, including occult micro-
metastases, make this approach infeasible. Systemic 
administration of radiopharmaceutical therapies 
(RPT) have the potential to deliver ablative doses to 
myriad lesions, and this modality has a long history of 
established clinical practice [1]. Here, pretherapeutic 
imaging and pharmacokinetic information of RPT 









at both sites of disease and to avoid off-target normal 
organ toxicities. 
There has been a growing interest in application 
of alpha particle (⍺)-emitting RPT for metastatic 
disease. Alpha particles are charged helium nuclei 
that deposit 5-10 MeV of energy in the range of only 
50-100 of microns, resulting in potent cytotoxicity. 
This produces complex DNA damage to both cancer 
cells and normal tissues relative to conventional 
radiotherapies. The biological impact and physical 
characteristics of these emissions make the 
quantitative imaging of the activity distribution 
essential in order to optimize administered activities, 
modify treatment plans, monitor accumulation, and 
mitigate toxicity. There are several ⍺-emitting 
radioisotopes with relevant biomedical properties 
including 212Pb (parent of ⍺-emitting 212Bi; t1/2 = 10.6 h) 
and 211At (t1/2 = 7.2 h). Among the most translationally 
relevant, and the focus of this work, are the 
longer-lived 223Ra (t1/2 = 11.4 days), which is approved 
for use in treatment of metastatic castrate-resistant 
prostate cancer (mCRPC), its parent, 227Th (t1/2 = 18.7 
days), and 225Ac (t1/2 = 10 days). 
Despite the long-standing interest, there are few 
reports of quantitative imaging methods for 
assessment of ⍺-RPT. Indeed, the combination of a 
complex photon emission spectrum and the very low 
activities administered to patients makes imaging of 
⍺-emitting radiopharmaceuticals challenging because 
of the low number of detectable photons. There is also 
a need to compensate for the scatter and septal 
penetration that constitutes a substantial part of the 
acquired signal. 
The efficacy of 223Ra in mCRPC patients has been 
demonstrated in multiple studies [2-11] and this 
radionuclide has three principal gamma emissions at 
81, 154, and 270 keV [12]. Multiple reports have 
shown that it is possible to acquire coarse imaging of 
223Ra using planar methods [13-16], primarily using an 
energy window centered on the 81 keV gamma 
emission. Such gamma camera planar imaging can be 
used to assess biodistribution and to calculate normal 
organ dosimetry in patients treated with 
223Ra-dichloride [14, 17-22], according to the Medical 
Internal Radiation Dose (MIRD) formalism. Recently, 
several studies have shown the feasibility of 
quantitative single-photon emission computed 
tomography (SPECT) [23-25] using physical-phantom 
measurements. For example, Gustafson et al. [24] 
showed that quantification of a 26.4 mL sphere in a 
NEMA IEC Body phantom was achievable with errors 
ranging from -25% to -34% with a GE Infinia 
Hawkeye SPECT/CT gamma-camera (GE, Fairfield, 
CT, USA) equipped with a medium-energy 
collimator. 
225Ac is currently used for antibody- and 
peptide-labeled therapies under pre- and clinical 
evaluation. In particular, there has been great interest 
in 225Ac-PSMA-617 in several investigational studies 
for patients with prostate cancer [26-28]. For patients 
with advanced disease, treatment activities of 100 
kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 
weeks have been administered [26, 27]. 225Ac has two 
principal gamma emissions at 218 keV and 440 keV 
[12] from its daughters 221Fr and 213Bi respectively, 
along with bremsstrahlung X-rays from 209Pb. 
Kratochwil et al. [28] have reported planar imaging of 
patients treated with 225Ac-PSMA-617 using energy 
windows centered around the two gamma emission 
lines previously noted. In addition, Usmani et al. 
recently demonstrated that addition of a 78 keV 
photopeak provided improved quality of images with 
a clearer distinction of lesions [29]. To the best of our 
knowledge, a single report of quantitative 225Ac 
imaging (for PSMA-targeted therapy) has been 
evaluated [30]. However, the 213Bi daughter has been 
investigated for tomographic imaging with 
213Bi-DOTATOC. These have shown promising initial 
results [31]. 
Finally, 227Th is also the subject of several 
early-phase clinical trials using antibody targeted 
vehicles, such as an alternative PSMA construct in 
mCRPC patients (NCT03724747) [32, 33]. 227Th has 
one principal gamma emission at 236 keV [12], and is 
the parent of 223Ra; thus, its gamma emissions can also 
be used for imaging. According to the work of Murray 
et al. [34], planar imaging of 227Th is achievable using 
multiple energy windows, and this approach may 
provide quantitative value. Quantification of a 3 cm 
diameter sphere in a water-filled cylinder phantom 
227Th filled phantom by SPECT provided values 
within an error of -12.4 ± 4.9%, using a Symbia Intevo 
(Siemens) gamma camera equipped with a medium 
energy-low penetration collimator [35]. 
These initial efforts for planar and tomographic 
imaging of 223Ra, 225Ac, and 227Th are encouraging. 
They motivate further characterization of the 
properties of SPECT-based activity quantification for 
⍺-RPT to allow for its use in patient studies to acquire 
reliable information about their accumulation in both 
sites of disease and at-risk organs. In general, SPECT 
is considered superior to planar imaging for activity 
quantification [36] with the primary advantage of 
eliminating organ activity overlap and enabling more 
accurate attenuation and scatter correction. 
The present studies investigate the feasibility 
and limitations of quantitative SPECT for 223Ra, 225Ac, 
and 227Th. A series of phantom measurements were 
performed on three state-of-the-art SPECT/CT 
systems: GE Discovery NM/CT 670, GE Optima 





NM/CT 640 and Siemens Symbia T6. This work 
describes and validates a methodology to calibrate 
each camera. The efficiency of each gamma camera is 
analyzed and compared, with a primary focus on the 
estimation of radioactivity concentration in lesions. 
The long-term goal is to characterize these properties 
to allow for future SPECT/CT-based patients studies 
and to identify the limiting factors for accurate 




In this work, three ⍺-emitters have been studied: 
223Ra, 225Ac, and 227Th. Figure S1 illustrates each 
radionuclide’s decay scheme and Table 1 summarizes 
the principal photon emissions. For imaging 
evaluation, five phantoms were used: the 
standardized NEMA IEC Body phantom, two custom 
detection-limit phantoms, a tumor phantom, and a 
vertebrae phantom. 225Ac and 227Th were supplied as 
dry nitrates from the Department of Energy (Oak 
Ridge National Laboratory) from 228Th and 
227Ac-generator systems, respectively. 227Th samples 
for spectroscopic and tomographic evaluation were 
chemically purified at maximum of one day prior to 
their use. Different sources of 223Ra solutions were 
used for these studies. Xofigo (223RaCl2) was used for 
energy spectrum and sensitivity measurements. For 
the NEMA phantom and the high activity limit of 
detection phantom, 223Ra was generated in our 
laboratory from trace 227Ac, as previously reported 
[37]. For the low activity limit of detection phantom 
and the vertebrae phantom, 223Ra was produced in 
our laboratory from 227Th. All samples used for 
measurement were quality controlled by high 
resolution gamma spectroscopy in order to verify 
their identical radiological properties (for 223Ra 
sources), and purity. A 1.5 mL conical polypropylene 
vial was filled with 37 kBq of each radioisotope were 
measured for 10 min on a high purity germanium 
(HPGe) system (GEM-50195-S; Ortec). Samples were 
placed directly on a high purity aluminum endcap 
and the system was enclosed in a 10 cm lead shield 
(HPLBS1, Ametek). Spectral acquisitions were 
acquired and analyzed by Gamma-Vision Software 
(version 8.0, Ametek). 
Activity measurements 
All sample activities were carefully measured 
with the same ionization chamber radionuclide dose 
calibrator (CRC-15; Capintec). The dial settings used 
for 223Ra, 225Ac, and 227Th are 236, 72, and 91, 
respectively. A National Institutes of Standards and 
Technology traceable source was used to empirically 
determine the dose calibrator value for 223Ra, as 
previously described [36]. A National Physics 
Laboratory (UK) traceable source, in preparation for 
investigation clinical treatment studies with antibody 
conjugates, was used to determine the dose calibrator 
value for 227Th, and verified by HPGe measurements. 
 
Table 1. Decay data for 223Ra, 225Ac and 227Th and their 
daughters. The bolded energies are within the ideal energy range 
of the gamma camera 
Isotope Half-life 
(days) 
Daughters Principal emitted photon energies 
(keV) (% abundance) 
223Ra 11.43     11.7 (25.0), 81.1 (15.0), 83.8 (24.9), 
94.9 (11.3), 144.2 (3.2), 154.2 (5.6), 
269.5 (13.7) and 323.9 (3.9) 
  219Rn    271.2 (10.8) and 401.8 (6.4) 
   211Pb   404.9 (3.8) and 832.0 (3.5) 
    211Bi  351.1 (12.9) 
225Ac 10     12.0 (6.9) and 14.8 (6.7) 
  221Fr    218.2 (11.6) 
    213Bi  440.5 (26.1) 
227Th 18.68     12.3 (21.0), 50.1 (8.0), 236.0 (12.3) 
and 256.3 (7.0) 
  223Ra    11.7 (25.0), 81.1 (15.0), 83.8 (24.9), 
94.9 (11.3), 144.2 (3.2), 154.2 (5.6), 
269.5 (13.7) and 323.9 (3.9) 
   219Rn   271.2 (10.8) and 401.8 (6.4) 
    211Pb  404.9 (3.8) and 832.0 (3.5) 
     211Bi 351.1 (12.9) 
 
SPECT/CT camera characteristics 
To evaluate vendor, collimator, and device- 
specific effects on low activity ⍺-emitter SPECT 
acquisition, we evaluated three dual-head SPECT/CT 
cameras: a Discovery 670 and an Optima 640 SPECT/ 
CT from GE and a Symbia T6 from Siemens. All the 
cameras were equipped with their specific set of 
collimators: MEGP (medium energy general purpose) 
for GE or MELP (medium energy low-penetration) for 
Siemens and HEGP (high-energy general purpose) for 
both vendors. Enclosed in Table 2 and Table 3 are the 
camera system and collimator characteristics of each 
unit, respectively. 
Energy spectrum and sensitivity comparison 
To set the energy windows for quantitative 
imaging, the energy spectrum of each radioisotope 
was measured on the Discovery 670 (GE) and Symbia 
T6 (Siemens) with both collimators. Since the gamma 
camera components from the Discovery 670 and the 
Optima 640 are identical, the energy spectrum was 
measured only on the Discovery 670. The source was 
contained in a 5 mL glass vial and placed in the center 
of the field of view between the two gamma camera 
heads at a point 17 cm from both heads. The activity 
in the source was 932 kBq, 2242 kBq, and 419 kBq for 
223Ra, 225Ac, and 227Th, respectively. 
 









Table 3. Collimator Characteristics 






GE 670 and 640 MEGP 3 1.05 58 
HEGP 4 1.8 66 
Siemens Symbia T6 MELP 2.94 1.14 40.64 
HEGP 3.4 2 50.8 
 
The Symbia T6 offers the possibility of directly 
measuring the energy spectrum without acquiring an 
image. For the measurement on the Discovery 670, the 
energy spectrum was assessed from planar images of 
each source, acquired using energy windows covering 
the range from 57 keV to 475 keV, totaling 59 energy 
windows for 223Ra and 227Th and 43 energy windows 
for 225Ac. Each acquisition was acquired for a duration 
of 5 min. The emission energy windows were selected 
to provide coverage of the relevant photopeaks 
specific for each radioisotope, and a corresponding 
scatter energy window was estimated on adjacent 
lower energies. 
In order to compare the performance of each 
system, the sensitivity was measured for each 
radioisotope and collimator. The same geometry and 
sources, as described above, were used. Planar images 
of each source, and an acquisition without any source 
for background subtraction, were recorded using the 
emission windows determined from the energy 
spectrum for a duration of 10 min. The sensitivity, 
denoted by S, was calculated as follows: 
𝑆 =  𝐶𝑜𝑢𝑛𝑡𝑠
𝐴×𝑇𝑎𝑐𝑞
  (1); 
where Counts denotes the total counts measured in a 
region of interest (ROI) with the same area as the vial 
and centered around it, after background subtraction; 
Tacq is the acquisition duration (s), and A denotes the 
nominal activity in the vial at the time of acquisition 
(MBq). 
Quantitative phantom study 
A NEMA IEC Body phantom (Data Spectrum) 
was used to investigate quantitative SPECT/CT 
imaging characteristics. The NEMA phantom contains 
6 spheres of different diameters: 3.7, 2.8, 2.2, 1.7, 1.3, 
and 1.0 cm. Each sphere was filled with the same 
activity concentration of the radioisotope: 40 kBq/mL 
for 223Ra, 35 kBq/mL for 225Ac, and 40 kBq/mL for 
227Th, with the main cavity of the phantom body filled 
with non-radioactive water. 
The phantom was placed in the center of the 
field of view and SPECT/CT acquisitions were 
performed with both MEGP/MELP and HEGP 
collimators on each system with energy windows 
determined from energy spectrum evaluation. The 
body-contour acquisition orbit was utilized and 30 s 
acquisitions per projection were acquired for every 6°, 
over a 360° orbit. 
The images acquired on the GE cameras were 
reconstructed on the Xeleris software with the 
following parameters: 2D-OSEM algorithm, 2 
iterations, 10 subsets and Butterworth filter (fc = 0.48, 
p = 10). The projections were corrected for scatter 
using the corresponding scatter windows and the 
dual-energy window (DEW) scatter-compensation 
method [38] and attenuation using the CT-based 
attenuation map. Indeed, during a SPECT/CT 
acquisition, one image was generated for each 
emission energy window and each scatter energy 





window. The software also acquired CT-based 
attenuation maps with attenuation coefficients 
corresponding to each emission energy window. 
Finally, the reconstructed images were summed to 
evaluate combinations of energy windows. 
The acquired data on the Symbia T6 were 
reconstructed on the Esoft workstation (Siemens) with 
the following parameters: 3D OSEM algorithm, 16 
iterations, 4 subsets and Gauss filter (FWHM = 9 mm). 
Attenuation correction was performed from the CT 
using manufacturer’s default parameters. They were 
not corrected for scatter, as this software does not 
enable scatter correction for multiple energy window 
acquisitions. Similar to the Xeleris software, the Esoft 
workstation reconstructs each energy window 
individually. Table 2 summarizes the acquisition and 
reconstruction parameters used for the evaluation of 
quantitative imaging of the phantom. 
The reconstructed images were analyzed using 
HERMES (v2.7.2, Hermes Medical Solutions). 
Volumes of interest (VOIs) defined on the CT images 
were applied to the SPECT data: 6 spheres of the same 
dimensions of the spherical inserts of the NEMA 
phantom. The total number of counts was obtained 
for each sphere. 
The calibration factor CF (counts/s/MBq) was 




where C denotes the total reconstructed counts within 
the target volume of interest, A is the activity present 
in the sphere at the time of acquisition and Tacq 
denotes the duration of the acquisition. 
To compare imaging noise metrics, the central 
slice traversing all six spheres was selected as the 
target slice for analysis. A total of 36 background 
spherical VOIs were defined for each sphere size (3.7, 
2.8, 2.2, 1.7, 1.3, and 1.0 cm diameter) by positioning 
12 background VOIs on the target slice, as well as on 
two neighboring slices (slice positions ± 20 mm) 
(Figure 1). The number of counts in each VOI was 
reported using HERMES Hybrid Viewer and they 
were used to calculate the signal to noise ratio (SNR) 
and background variability (BV) [40]. The SNR was 
defined as: 
𝑆𝑁𝑅 =  
𝐶ℎ𝑜𝑡−𝐶𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑠𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
  (3); 
where Chot denotes the number of counts detected in a 
hot sphere, Cbackground denotes the mean of number of 
counts detected in the corresponding background 
VOIs, and sbackground denotes the standard deviation of 
the background VOIs. 
 
Figure 1. Target slice of the SPECT/CT fusion of the NEMA phantom with activity- 
filled spheres. Location of VOIs for analysis are indicated, along with the background 
VOIs (corresponding to the largest sphere volume; 26.5 mL). This representative 
reconstruction of the phantom is of 223Ra acquired on the Discovery 670 with a 
MEGP collimator. 
 
At the low detected counts for αRPT, orders of 
magnitude reduced from conventional SPECT tracer 
studies (typically with 99mTc), the signal generated in 
background following reconstruction is not 
negligible. BV measures the variation of VOI means 
over multiple VOIs. It takes into account the scatter 
and the ensemble noise in the reconstructed image. 
The BV was calculated with the following: 
𝐵𝑉 =  




where mk denotes the mean of pixels in kth 
background VOI, 𝑚�  denotes the average of 
background VOI means over different VOIs and K 
denotes the number of background VOIs (K = 36). 
Limits of detection 
A laboratory-built phantom was created to 
assess the limits of detection for each system, 
configuration, and isotope. This phantom is 
comprised of six 5 mL conical polypropylene vials 
filled with a range of activity concentrations of each 
radioisotope and four 5 mL conical polypropylene 
vials filled with water arranged at the center (Figure 
2). To cover the entire range of physiologically 
relevant activities, two identical phantoms covering 
alternate ranges of activity were evaluated. In the first 
(high), vials contained 74, 37, 27.7, 18.5, 9.2, and 3.7 
kBq/mL of each radioisotope and in the second (low), 
the vials were filled with 20, 15, 5, 2, 1, and 0.5 
kBq/mL. SPECT/CT acquisitions were acquired of 
each limit of detection range, on each gamma camera 
and with both collimators. The acquisition and 
reconstruction parameters were identical to those 
described above. 





VOIs were defined as 10 ellipsoids surrounding 
each vial, applied as above. The total number of 
counts was obtained for each VOI and plotted in 
function of the concentration of the radioisotope in the 
vials. The limit of detection was achieved when the 
number of counts in the VOI around the hot vial was 
not above 10 times the number of counts in the 
background. The background is determined as the 
mean number of counts in the VOIs surrounding the 
water filled vials. 
Validation with anthropomorphic physical 
phantoms 
In order to validate the acquisition and 
reconstruction protocol, a realistic tumor phantom 
was imaged. In collaboration with the 3D Printing Lab 
at Washington University, we modeled volumes 
representative of a realistic tumor using 
patient-data-derived tumor properties (size, shape) 
and a vertebrae based on a patient CT image. 
Computer-aided designs (CADs) were created in 
Blender V 2.82. Molds and the lid of the phantom 
were printed on Formlabs Form 2 3D printer with 
elastic resin. Two fillable 3D phantoms were printed 
(Figure 13 and Figure S12) [41]. The printed vertebrae 
phantom was covered with a solution of Plaster of 
Paris (calcium sulfate hemihydrate) to accurately 
mimic bone attenuation. The volumes of the tumor 
and vertebrae phantoms were 12 mL and 15 mL, 
respectively. The choice of the tumor phantom 
volume was based on patient-data-derived tumor 
volume and on selecting a volume similar to one of 
the NEMA sphere for quantification purposes. The 
vertebrae phantom was filled with 40 kBq/mL of 
223Ra and the tumor phantom was filled with 35 
kBq/mL of 225Ac and 227Th. For each configuration, 
the phantom was fixed on the cylindrical insert inside 
the NEMA phantom, which was filled with 
non-radioactive water to recapitulate body scatter and 
attenuation features. 
A SPECT/CT acquisition on the Discovery 670 
gamma camera with the MEGP collimator was 
acquired for each phantom. The acquisition and 
reconstruction parameters are the same as those 
described above. A VOI was contoured on the CT and 
applied on the SPECT data and counts inside both 
tumor and vertebrae were determined. The activity in 
the tumor was estimated using the calibration factor 
as obtained from the experiments with the NEMA 
phantom and compared to the true activity. 
Results 
Radioisotopes 
Figure 3 (left panel) shows the high-resolution 
gamma spectra of each source of the radioisotope 
from measurements using the HPGe. The principal 
photon emissions described in Table 1 are detected. 
The characteristic gammas are 81.1, 83.8, 94.9, 154.2, 
and 269.5keV for 223Ra; 218.2 and 440.5 keV for 225Ac, 
and 236 keV for 227Th. 
Energy spectrum 
The energy spectrum for each isotope measured 
on the Discovery 670 and the 
Symbia T6 are shown in Figure 3 
middle and left panel, respectively. 
The characteristic photopeaks of 
each isotope were measured and 
defined by both gamma cameras. 
For 223Ra, the 81.1 (15.0%), 83.8 
(24.9%), and 94.9 keV (11.3%) 
emissions were detected in a same 
peak as were the 269.5 (13.7%) and 
271.2 keV (10.8%) emissions because 
of the limited gamma camera 
energy resolution. The photons at 
351.1 keV (12.9%) from 211Bi was 
also visible in a photopeak at 350 
keV. Moreover, the Symbia T6 
measured both gammas at 401.8 
(6.4%) and 404.9 keV (3.8%) in one 
peak with the MELP collimator, 
contrary to the Discovery 670, 
which did not resolve this emission. 
For 225Ac, two photopeaks 
apart from characteristic X-rays 
(around 80 keV) coming from the 
 
 
Figure 2. Limit of detection phantom scanned by the Optima 640 gamma-camera. The six identical conical 
polypropylene vials are filled with different concentrations of 223Ra: 74, 37, 27.7, 18.5, 9.2, and 3.7 kBq/mL. The red 
circles denote the vials containing the hot sources while the green circles denote the vials filled with water. 





collimator were visible: the one at 218.2 keV (11.6%) 
from 211Fr and at 440.5 keV (26.1%) from 213Bi. We 
observed that while the characteristic 440 keV 
emission of the 213Bi daughter of 225Ac was detected 
appropriately at 440 keV on the Symbia T6, this 
emission line was identified at 410 keV on the 
Discovery 670. On both gamma cameras, we noted a 
significant down scatter peak around 170 keV. 
For 227Th, several peaks apart from the combined 
peaks for characteristic X-rays (around 82 keV) were 
visible. For example, the 236 keV (12.3%) gammas 
from 227Th were detected. Moreover, the Symbia T6 
gamma camera measured the 50.1 keV (8.0%) gammas 
from 227Th, contrary to the Discovery 670 on which we 
observed a decrease in signal, an aberration that may 
be due to a specific energy channel issue with our 
system. As the 227Th source was purified the day 
before the measurement, the characteristic gammas of 
223Ra were not discernable. 
The emission and scatter energy windows 
selected from the energy spectra measurements are 
summarized in Table 4 and Table 5 for the GE and the 
Symbia T6 Siemens SPECT/CT, respectively. Scatter 
windows were not used for the Symbia T6 system, as 
the system software does not allow the scatter 
correction on multiple energy windows acquisition. 
 
 
Figure 3. High resolution and clinical imaging system derived energy spectra of: A) 223Ra, B) 225Ac, C) 227Th. Left column: energy spectra measured by HPGe. Middle column: 
energy spectra measured on the Discovery 670 (GE) with the MEGP and HEGP collimators. Right column: energy spectra measured on the Symbia T6 (Siemens) with the MELP 
and HEGP collimators. The shaded areas are the chosen emission energy windows for SPECT evaluation. 
 
Table 4. Emission and scatter energy windows chosen for each radioisotope on the Discovery 670 (GE) 
Windows 223Ra 225Ac 227Th 
Emission windows Scatter windows Emission windows Scatter windows Emission windows Scatter windows 
I 85 keV ± 20% 57 keV ± 17,5% 80 keV ± 20% 57 keV ± 10.7% 50 keV ± 17.5% 36 keV ± 13.8% 
II 154 keV ± 20% 113 keV ± 8.8% 217.5 keV ± 8% 165 keV ± 21.2% 82 keV ± 19% 62.5 keV ± 5.6% 
III 270 keV ± 10% 226.5 keV ± 7,2% 410 keV ± 6.1% 365.5 keV ± 4.8% 239 keV ± 9% 200 keV ± 5% 
 
Table 5. Emission and scatter energy windows chosen for each radioisotope on the Symbia T6 (Siemens) 
Windows 223Ra 225Ac 227Th 
I 85 keV ± 20% 82 keV ± 20% 50.6 keV ± 20% 
II 154 keV ± 20% 216.8 keV ± 8% 85.7 keV ± 15% 
III 270 keV ± 10% 444.3 keV ± 5% 240 keV ± 9% 






Figure 4. Sensitivities measured on the three gamma cameras with both collimators, for the three isotopes: 223Ra (top), 225Ac (middle), 227Th (bottom). The energy windows I, 
II and III are: 85 keV ± 20%, 154 keV ± 20%, and 270 keV ± 10% for 223Ra; 82 keV ± 20%, 216.8 keV ± 8%, and 444.3 keV ± 5% for 225Ac; 50.6 keV ± 20%, 85.7 keV ± 15%, and 
240 keV ± 9% for 227Th. 
 
Figure 5. SPECT/CT fusion of the NEMA phantom acquired on the Discovery 670 (GE) with the HEGP collimator. Images are of A) Spheres filled with 40 kBq/mL of 223Ra; B) 
spheres filled with 35 kBq/mL of 225Ac, C) spheres filled with 40 kBq/mL of 227Th. 
 
The sensitivities measured for 223Ra, 225Ac and 
227Th for each gamma camera configuration and each 
emission window are presented in Figure 4. For each 
isotope, the results obtained on the Symbia T6 with 
the MELP collimator yielded the greatest computed 
sensitivity. For each isotope, the sensitivity of the 
HEGP collimator was lower than that determined 
with the MEGP/MELP collimator. Measurement with 
223Ra achieved their highest sensitivity when 
summing the three energy windows, which was 
consistent across images using the MEGP/MELP 
collimators for the three isotopes (Figure 3, left 
column). 
Quantitative phantom study 
Figure 5 shows the reconstructed fused 
SPECT/CT images of the NEMA phantom for the 
three isotopes with the Discovery 670 SPECT/CT 
equipped with the HEGP collimator. The emission 
and scatter energy windows used for each isotope and 
each gamma camera are summarized in Table 4 and 
Table 5. 
As expected from the sensitivity results (Figure 
4), the resulting SPECT/CT images with 223Ra had the 
greatest number of counts in the reconstructed 
volumes. Except in the smallest sphere (20.8 kBq for 





223Ra and 227Th and 18.2 kBq for 225Ac), all of the 
spheres were visible. For brevity, representative 
reconstructions for all additional data are presented in 
the Supplemental Data. 
For each reconstructed image and each sphere 
dimension, the CF, SNR and BV were assessed. 
Ra-223 
As shown in Figure 8, on the Discovery 670 (GE), 
the highest SNR with the MEGP and HEGP 
collimators was obtained with the window I (85 keV ± 
20%) and the window III (270 keV ± 10%), 
respectively. Compared to the MEGP collimator, the 
HEGP gave a higher calibration factor values: 2.5% 
more for the largest sphere (3.7 cm diameter). 
However, the BV was higher (1.3% for the largest 
sphere-volume compared to the MEGP collimator) 
and the SNR was lower. For instance, in the case of the 
largest sphere, the SNR was 1.4% lower with the 
HEGP collimator than with the MEGP collimator. 
Analyzing imaging data from the Optima 640 
(GE) showed that SNR for the window III was greater 
with the HEGP collimator than with the MEGP 
collimator (Figure S2). The MEGP collimator gave a 
higher calibration factor and SNR; for example, with 
the second largest sphere (2.8 cm diameter), they were 
5.3% and 1.3% greater than with the HEGP collimator. 
However, the BV was increased: 6.1% for the second 
largest sphere compared to the HEGP collimator. 
Similarly, using the Symbia T6 (Siemens), the 
HEGP collimator yielded improved SNR for the 
window III (Figure S3). Acquisitions with the MELP 
collimator provided a higher calibration factor: 6.8% 
greater for the largest sphere than with the HEGP 
collimator. However, the BV was increased: 2.0% for 
the largest sphere compared to the HEGP collimator. 
The HEGP collimator gave increased SNR: 8.3% 
higher for the largest sphere. 
To summarize, for 223Ra acquisition parameters 
and quantitative SPECT image metrics, the Symbia T6 
with the HEGP collimator has given the highest 
calibration factor and the lowest BV. However, except 
for the largest sphere volume, the acquisitions using 
the Discovery 670 with the HEGP collimator resulted 
in greater SNR. 
Ac-225 
Using the Discovery 670 with the MEGP 
collimator without scatter correction provided 
improved imaging results (Figure S4) than with 
correction, and these data are consistent with the 
energy spectrum analysis. Indeed, the calibration 
factor and SNR were 11.8% and 3.6% higher for the 
largest sphere than with scatter correction. However, 
the BV was 3.4% greater without scatter correction. 
The results were similar for the HEGP collimator 
(Figure S5). The calibration factor, BV and SNR were 
12.9%, 0.8% and 10.9% higher for the second largest 
sphere compared to with scatter correction. To 
summarize, the calibration factor for every sphere was 
similar with both collimators (only 1.4% different with 
the MEGP collimator for the largest sphere than with 
the HEGP collimator, which was not significant) and a 
lower BV. However, the SNR was higher with the 
HEGP collimator: 8.8% for the largest sphere 
compared to the MEGP collimator. 
Similarly, using the Optima 640 with MEGP 
collimation also demonstrated improved results 
without scatter correction (Figure 7 and Figure S6). 
The calibration factor and SNR were 13.3% and 3.6% 
greater for the largest sphere than with scatter 
correction. However, the BV increased by 2.6%. The 
HEGP collimator also provided better results without 
scatter correction (Figure 9). The calibration factor and 
SNR were 14.6% and 12.6% greater for the second 
largest sphere than with scatter correction. However, 
the BV was 3.0% greater. In summary, the HEGP 
collimator offered a similar calibration factor (1.1% for 
the largest sphere compared to MEGP, which was not 
significant) and increased SNR (5.6% for the largest 
sphere). Moreover, the BV was higher with the MEGP 
collimator: 10.6% for the largest sphere. 
On the Symbia T6, the HEGP collimator offered a 
better calibration factor and SNR: 3.7% and 5.6% for 
the largest sphere (Figure S7). However, the BV was 
higher with the HEGP collimator: 6.6% for the largest 
sphere. 
Overall, the Symbia T6 with the HEGP 
collimator gave the highest calibration factor and SNR 
across the systems tested for 225Ac. For example, in the 
case of the largest sphere, it was 49.7% and 9.5% more 
than the Discovery 670 and 49.7% and 2.5% higher 
than the Optima 640. However, the BV was also 
increased for the largest sphere obtained with the 
Symbia T6: 5.7% compared to the Discovery 670 and 
6.7% to the Optima 640. 
Th-227 
Acquisitions using the Discovery 670 showed 
that the window I (50 keV ± 17.5%) and the window 
III (239 keV ± 9%) had similar calibration factors with 
the MEGP collimator (Figure S8). The window II (82 
keV ± 19%) offered the highest calibration factor and 
the 239 keV emission window the highest SNR. The 
results were slightly better without scatter correction. 
Indeed, the calibration factor and SNR were 3.2% and 
1.1% higher than with scatter correction for the largest 
sphere. These observations were the same for the 
HEGP collimator (Figure S9). The calibration factor 
and SNR were 3.0% and 0.8% higher than with scatter 





correction for the largest sphere. Consequently, the 
MEGP collimator offered a better calibration factor 
and SNR: 2.5% and 7.6% for the second largest sphere 
compared to the HEGP collimator. Moreover, the BV 
was higher with the HEGP collimator: 1.0% for the 
second largest sphere. 
On the Optima 640 system, the calibration 
factors, SNR and BV were also similar for the MEGP 
and HEGP collimators. For both collimators, the 
windows I and III (50 keV and 239 keV) had similar 
calibration factors. The second emission window (82 
keV) offered the highest calibration factor, which was 
consistent with the sensitivity results (Figure S10 and 
Figure S11). With the MEGP collimator, the 
calibration factor was higher without scatter 
correction: 2.9% for the second largest sphere. 
However, the SNR was higher and the BV was lower 
with scatter correction: 2.2% and 2.1% for the second 
largest sphere. With the HEGP collimator, the 
calibration factor and SNR were higher without 
scatter correction: 3.3% and 0.6% for the largest 
sphere. As a result, the HEGP collimator gave a higher 
calibration factor: 3.0% for the second largest sphere. 
However, the SNR was higher and the BV was lower 
with the MEGP collimator: 5.5% and 5.5% for the 
second largest sphere. 
On the Symbia T6, the MELP collimator offered a 
better calibration factor and SNR: 12.6% and 9.4% for 
the second largest sphere. However, the BV was 
higher: 3.2% for the second largest sphere (Figure 6 
and Figure 10). 
To summarize, the Symbia T6 with the MEGP 
collimator gave the highest calibration factor and 
SNR: 49.5% and 10.7% compared to the Discovery 670 
and 49.5% and 9.4% compared to the Optima 640 for 
the largest sphere. Moreover, the BV was less 
important in the images obtained with the Symbia T6: 
6.9% compared to the Discovery 670 and 4.8% 
compared to the Optima 640 for the largest sphere. 
Figure 11 recapitulates the calibration factor, 
SNR and BV measured for the three isotopes on the 
optimally determined configuration for each system. 
Limit of detection 
Figure 12 shows an example of the SPECT/CT 
acquisition of the detection limit measurements. For 
the high activity phantom, all of the sample activities 
were visible except the lowest activity concentration 
(3.7 kBq/mL) (Figure 12A-C). Using the phantom 
with a lower activity concentration range; only the 
three higher activity concentrations were detectable 





Figure 6. SPECT/CT fusion of the NEMA phantom acquired on the Symbia T6 (Siemens) with the MELP collimator. The phantom was filled with 40 kBq/mL of 227Th. A) 




Figure 7. SPECT/CT fusion of the NEMA phantom acquired on the Optima 640 (GE) with the MEGP collimator. The phantom spheres were filled with 35 kBq/mL of 225Ac. A) 
Reconstructed image of the 217.5 keV ± 8% emission window without scatter correction, B) Reconstructed image of the 217.5 keV ± 8% emission window with scatter 
correction. 






Figure 8. Calibration factors, SNR and BV measured on SPECT/CT images of the NEMA phantom filled with 223Ra for each energy window and combination of the energy 
windows. Representative data acquired on the Discovery 670 (GE) with the MEGP (left column) and HEGP (right column) collimators. 
 
The detection limits phantoms filled with 223Ra 
and 227Th were imaged with the Discovery 670 (GE) 
equipped with a HEGP collimator and the MEGP 
collimator, respectively. The detection-limit phantoms 
filled with 225Ac were imaged with the Symbia T6 
(Siemens) equipped with a HEGP collimator. The 
limit of detectability was determined as 5 kBq/mL for 
every isotope, and the linearity of response was also 
assessed (Figure 12D). 
Validation with anthropomorphic physical 
phantoms 
In order to evaluate tomographic image quality 
in a controlled real-world scenario, we evaluated 
anthropomorphic 3D-printed structures. Figure 13 
and Figure S12 show SPECT/CT acquisitions of the 
vertebrae and tumor phantoms (described in 
Methods) filled with 223Ra, 225Ac, and 227Th. Table 6 
summarizes quantification of these images obtained 
by using the calibration factor measured on the 
NEMA phantom for the largest sphere [36]. The 
results show the possibility to quantifying the activity 
of 223Ra and 225Ac with an error lower than 4%. In the 
case of 227Th, quantification was still possible but with 
a substantially larger error. 
Table 6. Summary of quantification results with the 3 isotopes 
measured on calibrated SPECT/CT images acquired on the 
Discovery 670 with the MEGP collimator 
Isotope Real activity (MBq) Measured activity (MBq) Error (%) 
223Ra 0.597 0.609 2.1 
225Ac 0.401 0.386 3.5 
227Th 0.404 0.356 11.8 
 
Discussion 
This study investigates the capabilities to acquire 
and quantify SPECT of three ⍺-emitting radioisotopes: 
223Ra, 225Ac, and 227Th at activity levels commensurate 
with RPT applications on clinically relevant imaging 
systems. Three state-of-the-art gamma cameras that 
are widely deployed for conventional diagnostic 
nuclear medicine applications were evaluated: the 
Discovery 670 and Optima 640 from GE and the 
Symbia T6 from Siemens, and energy windows and 
collimator settings were tested for their impact on 
image quantitation.  
Of the α-emitting agents used in imaging 
studies, parameters for 223Ra and 225Ac with planar 
imaging have been the most widely reported [13-15, 
18, 19, 21, 22, 28, 42]. Quantitative SPECT 





investigations are much less common, involving both 
223Ra [23-25] and 225Ac [43-46]. Most recently, a case 
report has demonstrated the feasibility of dosimetry 
on a patient with a PSMA-targeted 225Ac agent [30]. 
The authors used HEGP collimation and two (218 keV 
and 440 keV) energy windows, but quantification of 
activity concentration was not reported. To date, no 
peer reviewed study of 227Th SPECT/CT has been 
published, despite the active interest in this area [47] 
and the potential of scintigraphy for 227Th 
quantification [48]. 
To comprehensively evaluate ⍺-emitter SPECT, 
an optimized acquisition protocol was first 
determined for each isotope. To that end, an energy 
spectrum was acquired on both the GE Discovery 670 
and the Siemens Symbia T6 in order to determine 
appropriate energy windows. Diverging from the 
most commonly used tracers (Technetium-99m and 
Indium-111), the reconstruction protocol was 
optimized by acquiring SPECT/CT of the NEMA 
phantom. We used vendor-recommended recon-
struction parameters, including the number of 
iterations and subsets and post-reconstruction filters. 
These reconstruction parameters varied between 
systems. The role of scatter correction in activity 
estimation was investigated, along with limits of 
detection, for each isotope and each system. Finally, 
the acquisition and reconstruction protocol were 
validated using anthropomorphic 3D-printed 
phantoms. 
Our data establish that three-energy emission 
windows are recommended in order to provide 
higher count statistics and improve the image quality. 
While SNR can degrade with a multiwindow 
approach, the improved sensitivity is important 
towards the eventual goal of quantification of patient 
tissue activity concentrations. Scatter correction using 
the DEW technique is not recommended for 225Ac and 
227Th as it decreases sensitivity. However, scatter 
correction has the intended effect of decreasing noise 
in reconstructions. Since these ⍺-emitters have low 
detectable photons, we suggest that sensitivity is an 
important study design criterion. More recently, 
methods that been proposed which use the 
scatter-window data for the quantification task [49], 
which may achieve the goals of both improving 
sensitivity and accomplishing scatter correction. 
 
 
Figure 9. Calibration factors, SNR and BV measured on SPECT/CT images of the NEMA phantom filled with 225Ac for each energy window and combination of energy windows. 
The images were acquired on the Optima 640 (GE) with the HEGP collimator with scatter correction (left column) and without (right column). 






Figure 10. Calibration factors, SNR and BV measured on SPECT/CT images of the NEMA phantom filled with 227Th for each energy window and combination of energy windows. 
The representative data were acquired on the Symbia T6 (Siemens) with the MELP (left column) and HEGP (right column) collimators. 
 
Figure 11. Comparison of the calibration factors, SNR and BV between gamma cameras for the three isotopes. Left: Radium. The NEMA phantom was acquired with the HEGP 
collimator for the Discovery 670 and the Symbia T6 and with the MEGP collimator for the Optima 640. Center: Actinium. The NEMA phantom was acquired with the HEGP 
collimator for the Optima 640 and the Symbia T6 and with the MEGP collimator for the Discovery 670. Right: Thorium. The NEMA phantom was imaged with the MEGP/MELP 
collimator for the three gamma-camera. 






Figure 12. Transaxial and coronal slice from the SPECT/CT fusion of the Limit of Detection phantom acquired on the Discovery 670 (GE) with the MEGP collimator for 227Th. 
A) Limit of detection phantom with higher activities scale of 227Th. B) SPECT of lower scale limit of detection phantom. C) Gradient of activities per sample arranged in order of 
activity concentration (high: 74, 37, 27.7, 18.5, 9.2 and 3.7 kBq/mL, and low: 20, 15, 5, 2, 1 and 0.5 kBq/mL). D) Plot of the number of reconstructed counts detected in the hot 
tubes as a function of concentration. 
 
The NEMA phantom studies allow one to adapt 
the calibration factor for different lesion sizes [39]. The 
calibration factor determined from our acquisitions 
decreases with decreasing sphere volume. For smaller 
spheres, the visual contrast and calibration factor 
decreased due to partial volume effects. The 
3D-printed tissue phantoms showed that 
quantification is achievable with the three 
alpha-emitters on the three different systems. 
The choice of the collimator is a tradeoff between 
the sensitivity of the measurement and the observed 
signal to noise ratio. The characteristics of both 
collimators used for each system were summarized in 
Table 3; briefly, the MEGP collimator has smaller hole 
diameter and thinner and shorter septa. The HEGP 
collimator prevents more unscattered photons from 
being detected compared to the MEGP 
collimator owing to the thicker and taller 
septum. The thicker septa help reduce the 
septal penetration by higher energy 
photons. This explains why the SNR 
measured in the higher energy window 
with the HEGP collimator is greater the 
MEGP, for each isotope. 
At our center, for the imaging of 223Ra, 
we recommend using the Discovery 670 
with the HEGP collimator. The HEGP and 
Symbia T6 is recommended for imaging 
225Ac. Finally, the Symbia T6 with the 
MEGP collimator is suggested for imaging 
227Th. These configurations are derived 
from a compromise between sensitivity 
and noise characteristics, illustrated in 
Figure 11. Overall, our findings also 
demonstrate that the Symbia T6 is more 
sensitive under the test conditions. This 
result might be explained by the larger 
crystal dimensions, as well as differences 
in signal processing electronics. The calibration factor 
measured on the Symbia T6 is 50% higher than the 
one assessed on both GE cameras for each sphere and 
isotope evaluated. 
We have observed that under our experimental 
SPECT conditions, system configuration and image 
quality with 223Ra was greater than for 225Ac and 227Th. 
This is likely due to the fact that the gamma emission 
abundance for 223Ra exceeds that of the other isotopes 
and its photopeaks coincide with a range (100-300 
keV) for which detector efficiency is highest. In 
addition, higher energy gamma rays, as observed 
with 225Ac, cause performance degrading effects such 
as increasing septal penetration and down-scatter that 
complicate reconstruction and quantification tasks. 
 
Figure 13. 3D-printed Vertebrae phantom. A) Picture of a 3D printed Vertebrae. B) CAD of the 
Vertebrae showing the fillable space. C) The Vertebrae phantom was fixed on the cylindrical insert inside 
the NEMA phantom SPECT/CT images of the 3D-printed vertebrae phantom acquired on the Discovery 
670 with the MEGP collimator. Transaxial and Sagittal views of the Vertebrae phantom filled with 40 
kBq/mL of 223Ra. Top: CT view. Middle: NM view. Bottom: NM/CT fusion. 
 





Our measurements under the various 
experimental conditions in this work have import for 
interpretation and design of clinical SPECT/CT 
efforts. In clinical practice, patients receive 55 kBq/kg 
of 223Ra every 4 weeks for 6 cycles. Pharmacokinetic 
studies have shown that the principal organ at risk is 
the bone marrow [7, 17]. In Pacilio et al. [22] and 
Murray et al. [15], the authors reported an average 
total lesion size of 87 mL (1.2 to 270 mL in 14 patients 
and 53 lesions) for osteoblastic bone metastasis of 
prostate cancer. However, in the context of osteolytic 
bone metastasis of kidney cancer, the target of new 
clinical trials [50], lesions are much smaller (average 
volume of 0.6 mL specifically, 0.1-5.1 mL in 10 
patients and 66 lesions) [51]. Therefore, taking into 
consideration a limit of detection of 5 kBq/mL, the 
lowest detectable activity in an averaged sizes 
osteoblastic lesion would represent approximately 
10% of the injected activity for an 80 kg patient. In the 
case of an osteolytic lesion, it would represent about 
0.07% of the injected activity for the same patient. 
Thus, we predict that our protocol will enable the 
quantification of osteoblastic bone metastasis (with a 
significant uptake) whereas, for osteolytic bone 
metastasis, partial volume correction will be 
necessary to obtain a more robust quantification. 
A range of peptide and antibody 225Ac- 
formulated agents are under clinical trial evaluation. 
225Ac-PSMA-617 is perhaps the most well described 
[26-28]. Consequently, lesions dimensions are similar 
as described above for 223Ra. Our study shows that the 
quantification of 225Ac SPECT images is achievable. 
Recently, Gosewisch et al. demonstrates feasibility of 
quantitative SPECT imaging in a patient injected with 
225Ac-PSMA [30]. The authors used two energy 
windows centered on the 218 and 440 keV 
photopeaks. They were able to perform a dosimetry 
study on the patient kidneys and a small lesion. Renal 
clearance of low molecular weight radio-
pharmaceuticals makes the kidney an organ of 
considerable interest for these efforts. The use of a 
specific phantom such as a 3D-printed kidney 
phantom [52] may be necessary to properly calibrate a 
gamma camera for the specific task of quantitative 
alpha particle emitting agent SPECT. Indeed, studies 
have shown that spill-out effects become more 
relevant in organs whose shapes differ significantly 
from a spherical geometry and that sphere-based 
calibration factor lookup tables should be replaced by 
a more geometry-specific alternative [53, 54]. 
Moreover, VOI delineation for nonuniform structures 
is a significant contributor to uncertainty in RPT 
dosimetry [55], and it is important to optimize the 
calibration for ill-defined objects. Similarly, SPECT 
methods that quantify uptake directly from the 
projection data show promise for improved 
quantification even with non-spherical structures 
evaluated for 223Ra [56], and this approach may be 
expanded to include other emitters. 
Phase I clinical trials using 227Th conjugates 
targeting lymphoma, mesothelioma and prostate 
cancer are ongoing (NCT02581878, NCT03507452, 
NCT03724747). For 227Th-labeled anti-PSMA agents, 
as for 223Ra and 225Ac-labeled PSMA-inhibitors, our 
protocol demonstrates the feasibility of quantifying 
lesion uptake. Previous work by Hammer et al. [57] 
has identified the organs at risk as the liver and 
spleen. Similar to 225Ac, the use of organ specific 
phantoms may be necessary for accurate calibration of 
the gamma cameras. 
The initial daughter of 227Th is 223Ra, which may 
have an independent biodistribution to that of the 
parent conjugate. Quantitative in vivo imaging with 
conventional systems is challenging due to cross-talk 
between neighboring gammas as well as scattered 
gamma photons. This might explain a greater 
difference in the quantification results from our 
realistic phantoms studies. In the present study, all 
the 227Th acquisitions have been performed within 24 
h after purification, and further study may be 
required to evaluate quantification at later timepoints 
from in-growth of daughter emitters. Larsson et al. 
[48] and Murray et al. [34] have proposed a 
methodology using different energy windows for 
planar imaging in this context. Li et al. [56] proposed a 
multiple-energy-window projection-domain quantifi-
cation method that jointly estimates the regional 
activity uptake of both 227Th and 223Ra directly using 
the SPECT projection data from multiple energy 
windows. This method yielded accurate 
quantification and further work to validate planar and 
SPECT efforts are ongoing. 
A primary focus in this work was hardware 
configuration evaluation of multiple isotopes, 
however software considerations in the clinical setting 
are also important. The acquisition protocol for each 
isotope has been determined and optimized on each 
systems’ software, using settings recommended by 
the vendor. Nevertheless, the reconstruction and 
post-reconstruction settings used in this study could 
be further optimized for quantification. Indeed, 
precise reconstruction methods have to take into 
account the scatter and attenuation of each isotope 
emission in the system matrix of the iterative 
reconstruction algorithms. In our experience, clinical 
software workflows may not at this time be well 
suited for multiple photon emissions. Thus, more 
advanced methods, such as those based on Monte 
Carlo simulations, may help improve the accuracy of 
SPECT/CT reconstruction and thus quantify uptake 







SPECT/CT imaging is, and will continue to be, 
an important tool in the development of new 
therapeutic radiopharmaceuticals, as it provides a 
means to assess the biodistribution in patients 
following administration. However, great care has to 
be taking for system calibration and acquisition 
protocol development and implementation. The 
present work demonstrates quantification of 223Ra, 
225Ac, and 227Th activity on SPECT/CT images is 
feasible on standard double-headed SPECT/CT 
which are widely deployed in the field. Further, 
configurations have been elaborated that will enable 
accurate detection and quantitation of activity 
concentrations from α-emitters in clinical use. The 
methodology developed in this study will be useful 
for the other α emitting isotope of clinical interest 
such as 212Pb or 211At. 
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